As of: October 2026

FACT SHEET

COMPANY PROFILE

STRATEC SE (Frankfurt: SBS; Prime Standard, ISIN: DE000STRA555) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers integrated laboratory software and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain - from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

MANAGEMENT BOARD

Marcus Wolfinger

Dr. Claus Vielsack

Dr. Georg Bauer

Tanja Bücherl

SUPERVISORY BOARD

- Prof. Dr. Georg Heni
- Dr. Frank Hiller
- Dr. Patricia Geller
- Ralf Leistner
- Dr. Rolf Vornhagen

STOCK FUNDAMENTALS

ISIN	DE000STRA555
WKN	STRA55
Symbol	SBS
Reuters Code	SBSG.DE
Branch	Pharma & Healthcare
Transparency level	Prime Standard
Market segment	Regulated Market
Type of shares	Registered Shares
Registered capital	12,157,841 Euro
No. of shares	12.157.841
Initial listing	Aug 25, 1998
Stock exchanges	Xetra; Frankfurt am Main and other regional exchanges in Germany

SHAREHOLDER STRUCTURE

Investor group	**Share**
Fixed and family ownership (incl. investment companies)	40.36%
Treasury shares	0.02%
Free float	59.62%
Total	100.00%

STOCK CHART

As of: October 2026

FACT SHEET

KEY FIGURES AT A GLANCE [1]

IFRS (in € million)	2025	2024	2023 [2]	2022	2021
Sales	250.9	257.6	270.4	274.6	287.3
Adjusted EBIT	25.1	33.5	30.4	45.1	54.3
Adjusted EBIT margin (%)	10.0	13.0	11.2	16.4	18.9
Adjusted consolidated net income	14.2	20.5	19.0	34.7	45.1
Adjusted earnings per share (€)	1.17	1.69	1.56	2.86	3.73
Dividend per share (€)	0.60	0.60	0.55	0.97	0.95
No. of employees	1,403	1,450	1,522	1,481	1,398
Total assets	426.0	445.0	450.7	397.5	368.5
Equity ratio (%)	55.7	54.5	52.6	56.6	55.8

[1] For comparison purposes, adjusted figures have been adjusted to exclude amortization from purchase price allocations in the context of acquisitions, as well as for other one-off items (consulting and reorganization expenses in connection with M&A activities and one-off personnel expenses).

[2] Restated in accordance with IAS 8.

CONFERENCES

Nov 17, 2026	9th MidCap CEO Conference Organized by: BNP Paribas
Nov 24, 2026	German Equity Forum Organized by: Deutsche Börse - Analysts' Conference -
Nov 25, 2026	Digital Diagnostics Day Organized by: Kepler Cheuvreux

FINANCIAL CALENDAR

Nov 12, 2026	Publication Quarterly Statement 9M|2026

CONTACT

STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany

+49 7082 7916-0
www.stratec.com

Investor Relations
+49 7082 7916-991
ir@stratec.com